We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

76 hedge funds and large institutions have $143M invested in Avadel Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

90% more capital invested

Capital invested by funds: $75.5M → $143M (+$67.7M)

24% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 17

4% less ownership

Funds ownership: 57.15% → 53.16% (-4%)

7% less funds holding

Funds holding: 82 → 76 (-6)

29% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 14

38% less call options, than puts

Call options by funds: $5.54M | Put options by funds: $8.97M

Holders
76
Holders Change
-6
Holders Change %
-7.32%
% of All Funds
1.31%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
10
Increased
21
Reduced
17
Closed
14
Calls
$5.54M
Puts
$8.97M
Net Calls
-$3.43M
Net Calls Change
-$3.9M

Top Buyers

Rank Fund Capital Flow
1
GJL
Gendell Jeffrey L
+$2.9M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.86M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.22M
4
DMKJ
David M. Knott Jr
+$920K
5
MWM
Modera Wealth Management
New Jersey
+$677K

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$8.19M
2
BIP
Brandes Investment Partners
California
-$5.13M
3
PVI
Pura Vida Investments
New York
-$3.87M
4
Two Sigma Investments
Two Sigma Investments
New York
-$1.34M
5
Millennium Management
Millennium Management
New York
-$519K
Name Holding Trade Value Shares
Change 		Change in
Stake
LWAM
51
Legacy Wealth Asset Management
Minnesota
$65K – – –
CAN
52
Cetera Advisor Networks
California
$63K – – –
UBS Group
53
UBS Group
Switzerland
$60K +$49.4K +8,971 +301%
Wells Fargo
54
Wells Fargo
California
$58K -$523 -95 -0.8%
VF
55
Virtu Financial
New York
$53K +$58K +10,541 New
JSW
56
Journey Strategic Wealth
New Jersey
$50K +$55K +10,000 New
SG Americas Securities
57
SG Americas Securities
New York
$50K +$55.2K +10,021 New
PI
58
PineBridge Investments
New York
$37K – – –
QT
59
Quantbot Technologies
New York
$34K +$38K +6,900 New
LFG
60
Larson Financial Group
Missouri
$20K – – –
Zurich Cantonal Bank
61
Zurich Cantonal Bank
Switzerland
$18K -$1.75K -317 -8%
PCH
62
Polar Capital Holdings
United Kingdom
$14.1K – – –
SPIA
63
Steward Partners Investment Advisory
New York
$12K – – –
LC
64
Lindbrook Capital
California
$10K +$1.57K +286 +16%
US Bancorp
65
US Bancorp
Minnesota
$10K +$11.1K +2,010 New
Simplex Trading
66
Simplex Trading
Illinois
$10K +$11.6K +2,100 New
BCV
67
Banque Cantonale Vaudoise
Switzerland
$5K – – –
HFM
68
Hartford Financial Management
Connecticut
$5K – – –
Citigroup
69
Citigroup
New York
$3K -$1.1K -200 -23%
CUAMC
70
China Universal Asset Management Company
China
$3K +$3.04K +552 New
APA
71
American Portfolios Advisors
New York
$2.5K – – –
Rockefeller Capital Management
72
Rockefeller Capital Management
New York
$2K -$2.33K -424 -46%
BWP
73
Baldwin Wealth Partners
Massachusetts
$2K – – –
ARMC
74
American Research & Management Company
Massachusetts
$1K – – –
Daiwa Securities Group
75
Daiwa Securities Group
Japan
$1K – – –
1 2
3
4

AVDL Hedge Fund Activity: Q3 2022 in Review

76 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2022, worth a combined $143M — up 90% from $75.5M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of AVDL and 10 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 21 added.

The largest buyer was Gendell Jeffrey L, adding an estimated $2.9M. The largest seller was Woodline Partners, cutting an estimated $8.19M.

  • 76 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2022, down from 82 in Q2 2022.
  • Funds reported $143M of Avadel Pharmaceuticals stock for Q3 2022, up 90% quarter-over-quarter.
  • 10 funds opened new Avadel Pharmaceuticals positions in Q3 2022 and 14 closed out, a net change of -4 holders.
  • The largest Avadel Pharmaceuticals buyer in Q3 2022 was Gendell Jeffrey L, an estimated $2.9M added.
  • The largest Avadel Pharmaceuticals seller in Q3 2022 was Woodline Partners, an estimated $8.19M sold.

Based on aggregated 13F filings for Q3 2022.